Keywords: Fluorodeoxyglucose F18, Neoplasms, Therapy, Positron Emission Tomography, Cetuximab, Cisplatin, Fluorodeoxyglucose F 18, Fluorouracil, Folinic Acid, Irinotecan, Diagnostic Agent, Brain Tumor, Breast Cancer, Cancer Chemotherapy, Cancer Radiotherapy, Clinical Assessment, Colorectal Cancer, Computer Assisted Tomography, Diagnostic Procedure, Esophagus Cancer, Head And Neck Carcinoma, Human, Lung Non Small Cell Cancer, Monitoring, Outcome Assessment, Quantitative Analysis, Review, Stomach Cancer, Tissue Characterization, Treatment Response, Metabolism, Methodology, Treatment Outcome, Positron-Emission Tomography, X-Ray Computed,
Affiliations: *** IBB - CNR ***
IRCCS, CROB, Rionero in Vulture, Potenza, Italy
SDN Foundation, Institute of Diagnostic and Nuclear Development, Naples, Italy
Department of Biomorphological and Functional Sciences, University Federico II, Naples, Italy
References: Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L., New guidelines to evaluate the response to treatment in solid tumors (2000) J Natl Cancer Inst, 92, pp. 205-216. , European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canad
Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., New response evaluation criteria in solid tumours: Revised RECIST guideline (2009) Eur J Cancer, 45, pp. 228-247. , version 1.1
Fleming, T.R., Prentice, R.L., Pepe, M.S., Gidden, D., Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research (1994) Stat Med, 13, pp. 955-968
Junker, K., Langner, K., Klinke, F., Bosse, U., Thomas, M., Grading of tumor regression in non-small cell lung cancer: Morphology and prognosis (2001) Chest, 120, pp. 1584-1591
Vecchio, F.M., Valentini, V., Minsky, B.D., Padula, G.D., Venkatraman, E.S., Balducci, M., The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer (2005) Int J Radiat Oncol Biol Phys, 62, pp. 752-760
Mandard, A.M., Dalibard, F., Mandard, J.C., Marnay, J., Henry-Amar, M., Petiot, J.F., Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations (1994) Cancer, 73, pp. 2680-2686
Heinrich, S., Schäfer, M., Weber, A., Hany, T.F., Bhure, U., Pestalozzi, B.C., Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: Results of a prospective phase II trial (2008) Ann Surg, 248, pp. 1014-1022
Bacci, G., Ferrari, S., Bertoni, F., Picci, P., Bacchini, P., Longhi, A., Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy (2001) Clin Orthop Relat Res, 386, pp. 186-196
Rajan, R., Poniecka, A., Smith, T.L., Yang, Y., Frye, D., Pusztai, L., Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response (2004) Cancer, 100, pp. 1365-1373
Horiuchi, C., Taguchi, T., Yoshida, T., Nishimura, G., Kawakami, M., Tanigaki, Y., Early assessment of clinical response to concurrent chemoradiotherapy in head and neck carcinoma using fluoro-2-deoxy-d-glucose positron emission tomography (2008) Auris Nasus Larynx, 35, pp. 103-108
Brücher, B.L., Weber, W., Bauer, M., Fink, U., Avril, N., Stein, H.J., Neoadjuvant therapy of esophageal squamous cell carcinoma: Response evaluation by positron emission tomography (2001) Ann Surg, 233, pp. 300-309
Mac Manus, M.P., Hicks, R.J., Matthews, J.P., McKenzie, A., Rischin, D., Salminen, E.K., Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer (2003) J Clin Oncol, 21, pp. 1285-1292
Swisher, S.G., Maish, M., Erasmus, J.J., Correa, A.M., Ajani, J.A., Bresalier, R., Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer (2004) Ann Thorac Surg, 78, pp. 1152-1160
Ryu, J.S., Choi, N.C., Fischman, A.J., Lynch, T.J., Mathisen, D.J., FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: Correlation with histopathology (2002) Lung Cancer, 35, pp. 179-187
Bassa, P., Edmund Kim, E., Inoue, T., Wong, F.C.L., Korkmaz, M., Yang, D.J., Wong, W.-H., Podoloff, D.A., Evaluation of Preoperative Chemotherapy Using PET with Fluorine-18-Fluorodeoxyglucose in Breast Cancer (1996) Journal of Nuclear Medicine, 37 (6), pp. 931-938
Burcombe, R.J., Makris, A., Pittam, M., Lowe, J., Emmott, J., Wong, W.L., Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography (2002) Eur J Cancer, 38, pp. 375-379
Kim, S.J., Kim, S.K., Lee, E.S., Ro, J., Kang, S., Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy (2004) Ann Oncol, 15, pp. 1352-1357
Wahl, R.L., Zasadny, K., Helvie, M., Hutchins, G.D., Weber, B., Cody, R., Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation (1993) Journal of Clinical Oncology, 11 (11), pp. 2101-2111
Grigsby, P.W., Siegel, B.A., Dehdashti, F., Rader, J., Zoberi, I., Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: Response and outcome (2004) J Clin Oncol, 22, pp. 2167-2171
(1979) WHO Handbook for Reporting Results of Cancer Treatment, , Geneva (Switzerland): World Health Organization Offset Publication No. 48
Miller, A.B., Hogestraeten, B., Staquet, M., Winkler, A., Reporting results of cancer treatment (1981) Cancer, 47, pp. 207-214
James, K., Eisenhauer, E., Christian, M., Terenziani, M., Vena, D., Muldal, A., Therasse, P., Measuring response in solid tumors: Unidimensional versus bidimensional measurement (1999) Journal of the National Cancer Institute, 91 (6), pp. 523-528
Graf, W., Pahlman, L., Bergstrom, R., Glimelius, B., The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer (1994) British Journal of Cancer, 70 (3), pp. 559-563
Lavin, P., Mittelman, A., Douglass, H., Engström, P., Klaassen, D., Survival and response to chemotherapy for advanced colorectal adenocarcinoma (1980) Cancer, 46, pp. 1536-1543
Anderson, J.R., Cain, K.C., Gelber, R.D., Analysis of survival by tumor response (1983) J Clin Oncol, 1, pp. 710-719
Sörenson, S., Glimelius, B., Nygren, P., A systematic overview of chemotherapy effects in non-small cell lung cancer (2001) Acta Oncol, 40, pp. 327-339. , SBU-group. Swedish Council of Technology Assessment in Health Care
Gonzalez-Angulo, A.M., Morales-Vasquez, F., Hortobagyi, G.N., Overview of resistance to systemic therapy in patients with breast cancer (2007) Adv Exp Med Biol, 608, pp. 1-22
Ragnhammar, P., Hafström, L., Nygren, P., Glimelius, B., A systematic overview of chemotherapy effects in colorectal cancer (2001) Acta Oncol, 40, pp. 282-308. , SBU-group. Swedish Council of Technology Assessment in Health Care
Weiss, G.B., Bunce III, H., Hokanson, J.A., Comparing survival of responders and nonresponders after treatment: A potential source of confusion in interpreting cancer clinical trials (1983) Controlled Clinical Trials, 4 (1), pp. 43-52
Young, H., Baum, R., Cremerius, U., Herholz, K., Hoekstra, O., Lammertsma, A.A., Measurement of Clinical and Subclinical Tumor Response Using [18F]-fluorodeoxyglucose and Positron Emission Tomography: Review and 1999 EORTC Recommendations (1999) Eur J Cancer, 35, pp. 1773-1782. , on behalf of the European Organization for Research and Treatment of Cancer (EORTC) PET Study Group
Zasadny, K.R., Wahl, R.L., Standardised uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose:Variations with body weight and a method for correction (1993) Radiology, 189, pp. 847-850
Kim, C.K., Gupta, N.C., Dependency of standardised uptake values of fluorine-18 fluorodeoxyglucose on body size: Comparison of body surface area correction and lean body mass correction (1996) Nucl Med Commun, 17, pp. 890-894
Lammertsma, A.A., Brooks, D.J., Frackowiak, R.S.J., Beaney, R.P., Herold, S., Heather, J.D., Measurement of glucose utilisation with [18F]-fluoro-2-deoxy-d-glucose:A comparison of different analytical methods (1987) J Cereb Blood Flow Metab, 7, pp. 161-172
Sugawara, Y., Zasadny, K.R., Grossman, H.B., Francis, I.R., Clarke, M.F., Wahl, R.L., Germ cell tumor: Differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling (1999) Radiology, 211 (1), pp. 249-256
Brock, C.S., Young, H., Reilly, S.M., Matthews, J., Osman, S., Evans, H., Newlands, E.S., Price, P.M., Early evaluation of tumour metabolic response using [18F] fluorodeoxyglucose and positron emission tomography: A pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas (2000) British Journal of Cancer, 82 (3), pp. 608-615
Charnley, N., West, C.M., Barnett, C.M., Brock, C., Bydder, G.M., Glaser, M., Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy (2006) Int J Radiat Oncol Biol Phys, 66, pp. 331-338
Brun, E., Kjellen, E., Tennvall, J., Ohlsson, T., Sandell, A., Perfekt, R., FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma (HNSCC) (2002) Head Neck, 24, pp. 127-135
Schwarz, J.D., Bader, M., Jenicke, L., Hemminger, G., Janicke, F., Avril, N., Early prediction of response to chemotherapy in metastatic breast cancer using sequential18F-FDG PET (2005) Journal of Nuclear Medicine, 46 (7), pp. 1144-1150
Hoekstra, C.J., Stroobants, S.G., Smit, E.F., Vansteenkiste, J., Van Tinteren, H., Postmus, P.E., Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy- D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer (2005) J Clin Oncol, 23, pp. 8362-8370
Wieder, H.A., Brücher, B.L., Zimmermann, F., Becker, K., Lordick, F., Beer, A., Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment (2004) J Clin Oncol, 22, pp. 900-908
Ott, K., Herrmann, K., Lordick, F., Wieder, H., Weber, W.A., Becker, K., Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: Long-term results of a prospective study (2008) Clin Cancer Res, 14, pp. 2012-2018
Avril, N., Sassen, S., Schmalfeldt, B., Naehrig, J., Rutke, S., Weber, W.A., Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer (2005) J Clin Oncol, 20 (23), pp. 7445-7453
Wong, T.Z., Van Der Westhuizen, G.J., Coleman, R.E., Positron emission tomography imaging of brain tumors (2002) Neuroimaging Clin N Am, 12, pp. 615-626
Olivero, W.C., Dulebohn, S.C., Lister, J.R., The use of PET in evaluating patients with primary brain tumors: Is it useful? (1995) J Neurol Neurosurg Psychiatry, 58, pp. 250-252
Ricci, P.E., Karis, J.P., Heiserman, J.E., Fram, E.K., Bice, A.N., Drayer, B.P., Differentiating recurrent tumor from radiation necrosis: Time for reevaluation of positron emission tomography? (1998) AJNR, 19, pp. 407-413
De Witte, O., Hildebrand, J., Luxen, A., Goldman, S., Acute effect of carmustine on glucose metabolism in brain and glioblastoma (1994) Cancer, 74, pp. 2836-2842
O'Reilly, S.M., Newlands, E.S., Harte, R.J.A., Early changes in tumor glucose metabolism may predict and quantify response of gliomas to chemotherapy: A phase II study using temozolomide (1995) Proc Am Soc Clin Oncol, 14, p. 499
Holthoff, V.A., Herholz, K., Berthold, F., Widemann, B., Schröder, R., Neubauer, I., In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment (1993) Cancer, 72, pp. 1394-1403
Reisser, C., Haberkorn, U., Dimitrakopoulou-Strauss, A., Seifert, E., Strauss, L.G., Chemotherapeutic management of head and neck malignancies with positron emission tomography (1995) Arch Otolaryngol Head Neck Surg, 121, pp. 272-276
Berlangieri, S.U., Brizel, D.M., Scher, R.L., Schifter, T., Hawk, T.C., Hamblen, S., Coleman, R.E., Hoffman, J.M., Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy (1994) Head and Neck, 16 (4), pp. 340-346
Brun, E., Ohlsson, T., Erlandsson, K., Kjellen, E., Sandell, A., Tennvall, J., Wennerberg, J., Strand, S.-E., Early prediction of treatment outcome in head and neck cancer with 2-18FDG PET (1997) Acta Oncologica, 36 (7), pp. 741-747
Haberkorn, U., Strauss, L.G., Dimitrakopoulou, A., Seiffert, E., Oberdorfer, F., Ziegler, S., Reisser, C., Van Kaick, G., Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy (1993) Journal of Nuclear Medicine, 34 (1), pp. 12-17
Dalsaso, T.A., Lowe, V.J., Dunphy, F.R., Martin, D.S., Boyd, J.H., Stack, B.C., FDG PET and CT in evaluation of chemotherapy in advanced head and neck cancer (2000) Clin Positron Imaging, 3, pp. 1-5
Greven, K.M., Williams, D.W., Keyes Jr., J.W., McGuirt, W.F., Watson Jr., N.E., Randall, M.E., Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation (1994) Cancer, 74, pp. 1355-1359
Rege, S., Safa, A.A., Chaiken, L., Hoh, C., Juillard, G., Withers, H.R., Positron emission tomography: An independent indicator of radiocurability in head and neck carcinomas (2000) Am J Clin Oncol, 23, pp. 164-169
Higashi, K., Ueda, Y., Yagishita, M., Arisaka, Y., Sakurai, A., Oguchi, M., Seki, H., Yamamoto, I., FDG PET measurement of the proliferative potential of non-small cell lung cancer (2000) Journal of Nuclear Medicine, 41 (1), pp. 85-92
Kunkel, M., Forster, G.J., Reichert, T.E., Kutzner, J., Benz, P., Bartenstein, P., Radiation response non-invasively imaged by [18F]FDG PET predicts local tumor control and survival in advanced oral squamous cell carcinoma (2003) Oral Oncol, 39, pp. 170-177
Smith, I.C., Welch, A.E., Hutcheon, A.W., Miller, I.D., Payne, S., Chilcott, F., Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy (2000) J Clin Onco, 18, pp. 1676-1688
Schelling, M., Avril, N., Nährig, J., Kuhn, W., Römer, W., Sattler, D., Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer (2000) J Clin Oncol, 18, pp. 1689-1695
Mankoff, D.A., Dunnwald, L.K., Gralow, J.R., Ellis, G.K., Schubert, E.K., Tseng, J., Lawton, T.J., Livingston, R.B., Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy (2003) Journal of Nuclear Medicine, 44 (11), pp. 1806-1814
Gennari, A., Donati, S., Salvadori, B., Giorgetti, A., Salvadori, P.A., Sorace, O., Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients (2000) Clin Breast Cancer, 1, pp. 156-161
Weber, W.A., Petersen, V., Schmidt, B., Tyndale-Hines, L., Link, T., Peschel, C., Positron emission tomography in non-small-cell lung cancer: Prediction of response to chemotherapy by quantitative assessment of glucose use (2003) J Clin Oncol, 21, pp. 2651-2657
Eschmann, S.M., Friedel, G., Paulsen, F., Reimold, M., Hehr, T., Budach, W., 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer (2007) Eur J Nucl Med Mol Imaging, 34, pp. 463-471
De Geus-Oei, L.F., Van Der Heijden, H.F., Visser, E.P., Hermsen, R., Van Hoorn, B.A., Timmer-Bonte, J.N., Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer (2007) J Nucl Med, 48, pp. 1592-1598
Nahmias, C., Hanna, W.T., Wahl, L.M., Long, M.J., Hubner, K.F., Townsend, D.W., Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT (2007) J Nucl Med, 48, pp. 744-751
Couper, G.W., McAteer, D., Wallis, F., Norton, M., Welch, A., Nicolson, M., Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer (1998) Br J Surg, 85, pp. 1403-1406
Weber, W.A., Ott, K., Becker, K., Dittler, H.-J., Helmberger, H., Avril, N.E., Meisetschlager, G., Fink, U., Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging (2001) Journal of Clinical Oncology, 19 (12), pp. 3058-3065
Nakamura, R., Obara, T., Katsuragawa, S., Failure in presumption of residual disease by quantification of FDG uptake in esophageal squamous cell carcinoma immediately after RT (2002) Radiat Med, 20, pp. 181-186
Ott, K., Fink, U., Becker, K., Stahl, A., Dittler, H.J., Busch, R., Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: Results of a prospective trial (2003) J Clin Oncol, 21, pp. 4604-4610
Di Fabio, F., Pinto, C., Rojas Llimpe, F.L., Fanti, S., Castellucci, P., Longobardi, C., The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab (2007) Gastric Cancer, 10, pp. 221-227
Shinto, A., Nair, N., Dutt, A., Baghel, N.S., Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib (2008) Clin Nucl Med, 33, pp. 486-487
Guillem, J.G., Puig-La Jr., C.J., Akhurst, T., Tickoo, S., Ruo, L., Minsky, B.D., Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography (2000) Dis Colon Rectum, 43, pp. 18-24
Amthauer, H., Denecke, T., Rau, B., Hildebrandt, B., Hunerbein, M., Ruf, J., Schneider, U., Wust, P., Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: Correlation with endorectal ultrasound and histopathology (2004) European Journal of Nuclear Medicine and Molecular Imaging, 31 (6), pp. 811-819
Calvo, F.A., Domper, M., Matute, R., Martínez-Lázaro, R., Arranz, J.A., Desco, M., 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation (2004) Int J Radiat Oncol Biol Phys, 58, pp. 528-535
Langenhoff, B.S., Oyen, W.J., Jager, G.J., Strijk, S.P., Wobbes, T., Corstens, F.H., Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: A prospective study (2002) J Clin Oncol, 20, pp. 4453-4458
Joosten, J., Jager, G., Oyen, W., Wobbes, T., Ruers, T., Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases (2005) Eur J Surg Oncol, 31, pp. 1152-1159
Lubezky, N., Metser, U., Geva, R., Nakache, R., Shmueli, E., Klausner, J.M., The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: Comparison with operative and pathological findings (2007) J Gastrointest Surg, 11, pp. 472-478
Findlay, M., Young, H., Cunningham, D., Iveson, A., Cronin, B., Hickish, T., Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil (1996) J Clin Oncol, 14, pp. 700-708
Bender, H., Bangard, N., Metten, N., Bangard, M., Mezger, J., Schomburg, A., Biersack, H.-J., Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer (1999) Hybridoma, 18 (1), pp. 87-91
Rigo, P., Paulus, P., Kaschten, B.J., Hustinx, R., Bury, T., Jerusalem, G., Benoit, T., Foidart-Willems, J., Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose (1996) European Journal of Nuclear Medicine, 23 (12), pp. 1641-1674
Kasper, B., Dietrich, S., Dimitrakopoulou-Strauss, A., Strauss, L.G., Haberkorn, U., Ho, A.D., Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography (2008) Onkologie, 31, pp. 107-112
Bouchelouche, K., Oehr, P., Recent developments in urologic oncology: Positron emission tomography molecular imaging (2008) Curr Opin Oncol, 20, pp. 321-326
Avril, N.E., Weber, W.A., Monitoring response to treatment in patients utilizing PET (2005) Radiol Clin North Am, 43, pp. 189-204
Spaepen, K., Stroobants, S., Dupont, P., Van Steenweghen, S., Thomas, J., Vandenberghe, P., Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F] FDG) after first-line chemotherapy in non- Hodgkin's lymphoma: Is [18F]FDGPET a valid alternative to conventional diagnosis methods? (2001) J Clin Oncol, 19, pp. 414-419
Kostakoglu, L., Coleman, M., Leonard, J.P., Kuji, I., Zoe, H., Goldsmith, S.J., PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease (2002) J Nucl Med, 43, pp. 1018-1027
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., New response evaluation criteria in solid tumours: Revised RECIST guideline (2009) Eur J Cancer, 45, pp. 228-247. , version 1. 1
Fleming, T. R., Prentice, R. L., Pepe, M. S., Gidden, D., Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research (1994) Stat Med, 13, pp. 955-968
Vecchio, F. M., Valentini, V., Minsky, B. D., Padula, G. D., Venkatraman, E. S., Balducci, M., The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer (2005) Int J Radiat Oncol Biol Phys, 62, pp. 752-760
Mandard, A. M., Dalibard, F., Mandard, J. C., Marnay, J., Henry-Amar, M., Petiot, J. F., Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations (1994) Cancer, 73, pp. 2680-2686
Heinrich, S., Sch fer, M., Weber, A., Hany, T. F., Bhure, U., Pestalozzi, B. C., Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: Results of a prospective phase II trial (2008) Ann Surg, 248, pp. 1014-1022
Br cher, B. L., Weber, W., Bauer, M., Fink, U., Avril, N., Stein, H. J., Neoadjuvant therapy of esophageal squamous cell carcinoma: Response evaluation by positron emission tomography (2001) Ann Surg, 233, pp. 300-309
Mac Manus, M. P., Hicks, R. J., Matthews, J. P., McKenzie, A., Rischin, D., Salminen, E. K., Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer (2003) J Clin Oncol, 21, pp. 1285-1292
Swisher, S. G., Maish, M., Erasmus, J. J., Correa, A. M., Ajani, J. A., Bresalier, R., Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer (2004) Ann Thorac Surg, 78, pp. 1152-1160
Ryu, J. S., Choi, N. C., Fischman, A. J., Lynch, T. J., Mathisen, D. J., FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: Correlation with histopathology (2002) Lung Cancer, 35, pp. 179-187
Burcombe, R. J., Makris, A., Pittam, M., Lowe, J., Emmott, J., Wong, W. L., Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F] -fluorodeoxyglucose positron emission tomography (2002) Eur J Cancer, 38, pp. 375-379
Kim, S. J., Kim, S. K., Lee, E. S., Ro, J., Kang, S., Predictive value of [18F] FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy (2004) Ann Oncol, 15, pp. 1352-1357
Wahl, R. L., Zasadny, K., Helvie, M., Hutchins, G. D., Weber, B., Cody, R., Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation (1993) Journal of Clinical Oncology, 11 (11), pp. 2101-2111
Grigsby, P. W., Siegel, B. A., Dehdashti, F., Rader, J., Zoberi, I., Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: Response and outcome (2004) J Clin Oncol, 22, pp. 2167-2171
(1979) WHO Handbook for Reporting Results of Cancer Treatment, , Geneva (Switzerland): World Health Organization Offset Publication No. 48
Miller, A. B., Hogestraeten, B., Staquet, M., Winkler, A., Reporting results of cancer treatment (1981) Cancer, 47, pp. 207-214
Anderson, J. R., Cain, K. C., Gelber, R. D., Analysis of survival by tumor response (1983) J Clin Oncol, 1, pp. 710-719
S renson, S., Glimelius, B., Nygren, P., A systematic overview of chemotherapy effects in non-small cell lung cancer (2001) Acta Oncol, 40, pp. 327-339. , SBU-group. Swedish Council of Technology Assessment in Health Care
Weiss, G. B., Bunce III, H., Hokanson, J. A., Comparing survival of responders and nonresponders after treatment: A potential source of confusion in interpreting cancer clinical trials (1983) Controlled Clinical Trials, 4 (1), pp. 43-52
Zasadny, K. R., Wahl, R. L., Standardised uptake values of normal tissues at PET with 2- [fluorine-18] -fluoro-2-deoxy-d-glucose: Variations with body weight and a method for correction (1993) Radiology, 189, pp. 847-850
Kim, C. K., Gupta, N. C., Dependency of standardised uptake values of fluorine-18 fluorodeoxyglucose on body size: Comparison of body surface area correction and lean body mass correction (1996) Nucl Med Commun, 17, pp. 890-894
Lammertsma, A. A., Brooks, D. J., Frackowiak, R. S. J., Beaney, R. P., Herold, S., Heather, J. D., Measurement of glucose utilisation with [18F] -fluoro-2-deoxy-d-glucose: A comparison of different analytical methods (1987) J Cereb Blood Flow Metab, 7, pp. 161-172
Brock, C. S., Young, H., Reilly, S. M., Matthews, J., Osman, S., Evans, H., Newlands, E. S., Price, P. M., Early evaluation of tumour metabolic response using [18F] fluorodeoxyglucose and positron emission tomography: A pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas (2000) British Journal of Cancer, 82 (3), pp. 608-615
Schwarz, J. D., Bader, M., Jenicke, L., Hemminger, G., Janicke, F., Avril, N., Early prediction of response to chemotherapy in metastatic breast cancer using sequential18F-FDG PET (2005) Journal of Nuclear Medicine, 46 (7), pp. 1144-1150
Hoekstra, C. J., Stroobants, S. G., Smit, E. F., Vansteenkiste, J., Van Tinteren, H., Postmus, P. E., Prognostic relevance of response evaluation using [18F] -2-fluoro-2-deoxy- D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer (2005) J Clin Oncol, 23, pp. 8362-8370
Wieder, H. A., Br cher, B. L., Zimmermann, F., Becker, K., Lordick, F., Beer, A., Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment (2004) J Clin Oncol, 22, pp. 900-908
Wong, T. Z., Van Der Westhuizen, G. J., Coleman, R. E., Positron emission tomography imaging of brain tumors (2002) Neuroimaging Clin N Am, 12, pp. 615-626
Olivero, W. C., Dulebohn, S. C., Lister, J. R., The use of PET in evaluating patients with primary brain tumors: Is it useful? (1995) J Neurol Neurosurg Psychiatry, 58, pp. 250-252
Ricci, P. E., Karis, J. P., Heiserman, J. E., Fram, E. K., Bice, A. N., Drayer, B. P., Differentiating recurrent tumor from radiation necrosis: Time for reevaluation of positron emission tomography? (1998) AJNR, 19, pp. 407-413
O'Reilly, S. M., Newlands, E. S., Harte, R. J. A., Early changes in tumor glucose metabolism may predict and quantify response of gliomas to chemotherapy: A phase II study using temozolomide (1995) Proc Am Soc Clin Oncol, 14, p. 499
Holthoff, V. A., Herholz, K., Berthold, F., Widemann, B., Schr der, R., Neubauer, I., In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment (1993) Cancer, 72, pp. 1394-1403
Berlangieri, S. U., Brizel, D. M., Scher, R. L., Schifter, T., Hawk, T. C., Hamblen, S., Coleman, R. E., Hoffman, J. M., Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy (1994) Head and Neck, 16 (4), pp. 340-346
Dalsaso, T. A., Lowe, V. J., Dunphy, F. R., Martin, D. S., Boyd, J. H., Stack, B. C., FDG PET and CT in evaluation of chemotherapy in advanced head and neck cancer (2000) Clin Positron Imaging, 3, pp. 1-5
Greven, K. M., Williams, D. W., Keyes Jr., J. W., McGuirt, W. F., Watson Jr., N. E., Randall, M. E., Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation (1994) Cancer, 74, pp. 1355-1359
Rege, S., Safa, A. A., Chaiken, L., Hoh, C., Juillard, G., Withers, H. R., Positron emission tomography: An independent indicator of radiocurability in head and neck carcinomas (2000) Am J Clin Oncol, 23, pp. 164-169
Smith, I. C., Welch, A. E., Hutcheon, A. W., Miller, I. D., Payne, S., Chilcott, F., Positron emission tomography using [(18) F] -fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy (2000) J Clin Onco, 18, pp. 1676-1688
Mankoff, D. A., Dunnwald, L. K., Gralow, J. R., Ellis, G. K., Schubert, E. K., Tseng, J., Lawton, T. J., Livingston, R. B., Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy (2003) Journal of Nuclear Medicine, 44 (11), pp. 1806-1814
Weber, W. A., Petersen, V., Schmidt, B., Tyndale-Hines, L., Link, T., Peschel, C., Positron emission tomography in non-small-cell lung cancer: Prediction of response to chemotherapy by quantitative assessment of glucose use (2003) J Clin Oncol, 21, pp. 2651-2657
Eschmann, S. M., Friedel, G., Paulsen, F., Reimold, M., Hehr, T., Budach, W., 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer (2007) Eur J Nucl Med Mol Imaging, 34, pp. 463-471
De Geus-Oei, L. F., Van Der Heijden, H. F., Visser, E. P., Hermsen, R., Van Hoorn, B. A., Timmer-Bonte, J. N., Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer (2007) J Nucl Med, 48, pp. 1592-1598
Couper, G. W., McAteer, D., Wallis, F., Norton, M., Welch, A., Nicolson, M., Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer (1998) Br J Surg, 85, pp. 1403-1406
Weber, W. A., Ott, K., Becker, K., Dittler, H. -J., Helmberger, H., Avril, N. E., Meisetschlager, G., Fink, U., Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging (2001) Journal of Clinical Oncology, 19 (12), pp. 3058-3065
Guillem, J. G., Puig-La Jr., C. J., Akhurst, T., Tickoo, S., Ruo, L., Minsky, B. D., Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography (2000) Dis Colon Rectum, 43, pp. 18-24
Calvo, F. A., Domper, M., Matute, R., Mart nez-L zaro, R., Arranz, J. A., Desco, M., 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation (2004) Int J Radiat Oncol Biol Phys, 58, pp. 528-535
Langenhoff, B. S., Oyen, W. J., Jager, G. J., Strijk, S. P., Wobbes, T., Corstens, F. H., Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: A prospective study (2002) J Clin Oncol, 20, pp. 4453-4458
Avril, N. E., Weber, W. A., Monitoring response to treatment in patients utilizing PET (2005) Radiol Clin North Am, 43, pp. 189-204
[18F]FDG-PET-CT for early monitoring of tumor response: When and why
18F-fluorodeoxyglucose positron emission tomography ([ 18F]FDG PET) has been recognized as a suitable tool in tumor response assessment of patients complaining with solid tumors who have undergone chemo- and radiotherapy. It offers the advantage of functional tissue characterization, which is independent from morphologic criteria allowing to differentiate disease relapse from therapy-induced fibrosis. At present, there is a growing body of evidence that PET semi-quantitative assessment of treatment-induced changes in tumor [18F]FDG avidity may predict early tumor response and patient outcome. Patient management might be changed. For instance, in non responder patients this novel diagnostic approach would hamper useless "wait and watch" attitude in implementing further options or identifying those needing additional therapeutic strategies. On the other hand, for those patients revealing promptly a favourable metabolic response a cost-sparing approach could be implemented avoiding expensive diagnostic procedures during the follow-up as well as the risk of over-treating. In any case, since even a partial metabolic response may be an indication for continuing therapy, the advantage of metabolic assessment over conventional procedures may be clinically relevant. Although a morphological assessment has been considered for long time the standard for detecting therapy response, limitations of conventional computed tomography-based evaluation in solid tumors are well-known. PET provides an independent means of assessing malignancy. However, no consensus has been achieved until now regarding the optimal timing in performing PET during or at completion of treatment.
[18F]FDG-PET-CT for early monitoring of tumor response: When and why
Bruni AC, Bernardi L, Colao R, Rubino E, Smirne N, Frangipane F, Terni B, Curcio SA, Mirabelli M, Clodomiro A, Di Lorenzo R, Maletta R, Anfossi M, Gallo M, Geracitano S, Tomaino C, Muraca MG, Leotta A, Lio SG, Pinessi L, Rainero I, Sorbi S, Nee L, Milan G, Pappata S, Postiglione A, Abbamondi N, Forloni G, St George Hyslop P, Rogaeva E, Bugiani O, Giaccone G, Foncin JF, Spillantini MG, Puccio G * Worldwide distribution of PSEN1 Met146Leu mutation: A large variability for a founder mutation(761 views) Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2010 Mar 9; 74(10): 798-806. Impact Factor:8.017 ViewExport to BibTeXExport to EndNote
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(692 views) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 ViewExport to BibTeXExport to EndNote